Navigation Links
Oral Flu Vaccine On The Horizon In Russia

Russian researchers have developed an intranasal influenza vaccine using a novel adjuvant technology, with plans to develop what could become the first tablet// flu vaccine formulation.

The scientists, from Russia's Influenza Research Institute (RAMS) recently completed a preclinical study on intranasal formulation, with encouraging results. Clinical studies are due to start this autumn, and the vaccine will follow in the footsteps of a rival intranasal flu vaccine, MedImmune's FluMist, which is already on sale in the USA.

The adjuvant used in the vaccine, called Korauban, is an immunostimulant gamma interferon inductor that is closely related to ordinary cellulose. The initial clinical candidate form will include antigens from three inactivated viruses (A1, A2, B). An undisclosed component, permitting 12-month tablet stability, will be used to develop a vaccine in tablet form, said a spokesperson for RAMS.

”The combination of Korauban and vaccine viruses in one preparation leads to a synergy of their action,” said Professor Oleg Kuznetsov, RAMS project manager.

This is displayed in an increase in early synthesis of common interferon, a factor of the synthesis of intensified non-specific resistance of the organism of bacterial and viral infections.”

While adjuvants such as alum have been used in vaccines for decades, there has been interest of late in the development of newer adjuvants that offer more potent or selective immune stimulation. For example, around two-thirds of GlaxoSmithKline's vaccines in development are formulated with new proprietary adjuvant technologies.

Although, FluMist has been on the market since 2003, it remains a minor player compared to injectable flu vaccines, mainly because a requirement to store it frozen makes distribution and administration more complicated. Earlier this month the company won US approval to sell a new formulation that only needs refrigeration, and MedIm mune is hopeful this will kickstart sales. It sold 1.7 million doses of FluMist in the first nine months of 2006, bringing in $18 million in revenues.

Now, the Russian scientists are looking for funding of around $600,000 from investors to develop their technology, although the spokesperson said they may decide to sell it if the right offer is made.

The International Science and Technology Centre (ISTC), a non-profit non-commercial organization based in Moscow, supports the flu project.

Source: Bio-Bio Technology
SI
'"/>




Related medicine news :

1. Vaccine to quit smoking?
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Vaccine for Alzheimer’s diseas
4. Health Officials Recommend Flu Vaccine
5. Smallpox Vaccine May Help Fight Cervical Cancer
6. Panacea Biotech To Market Anthrax Vaccine
7. New Prostate Cancer Vaccine Shows Promise
8. Drug Firm Offers to Donate Smallpox Vaccine
9. Vaccine guards against shingles
10. Vaccine for septic conditions
11. A new Vaccine for Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... ... April 28, 2017 , ... From April ... of Urgent Care Medicine will host industry leaders for the annual spring Convention ... those in the industry adapt to the issues currently affecting urgent care and ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to ... “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore his ... of Greater Boston, in a NALA North American Speaker Series (NASS) segment. ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... for the North East region. Côté has 20+ years of experience within the ... Phytomer, Côté worked with an array of high-end cosmetic brands, retail brands and ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the launch ... a moisturizer with the power of an anti-aging concentrate. , Anogeissus ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets ... Pipeline and Market Prospects: Addressing Production Complexities Through Risk ... offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities ... in-depth assessment of the current trends in the global ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
Breaking Medicine Technology: